BioCentury
ARTICLE | Company News

Acumen Pharmaceuticals Inc., Merck deal

January 19, 2004 8:00 AM UTC

Acumen granted MRK exclusive worldwide rights to its amyloid-derived diffusible ligand (ADDL) target for use in developing monoclonal antibodies and vaccines to treat Alzheimer's disease (AD). Acumen ...